Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo

References

• RosaBde JesusJPde MelloELCesarDCorreiaMMEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisEcancermedicalscience2015958226557880
   PubMedGoogle Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin201363113023335087
   PubMed Web of Science ®Google Scholar
• CunninghamDAtkinWLenzHJColorectal cancerLancet20103751030104720304247
   PubMed Web of Science ®Google Scholar
• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer20101272893291721351269
   PubMed Web of Science ®Google Scholar
• AminMLockhartACThe potential role of immunotherapy to treat colorectal cancerExpert Opin Investig Drugs2015243329344
   PubMed Web of Science ®Google Scholar
• Van CutsemENordlingerBAdamRTowards a pan-European consensus on the treatment of patients with colorectal liver metastasesEur J Cancer200642142212222116904315
   PubMed Web of Science ®Google Scholar
• GallagherDJKemenyNMetastatic colorectal cancer: from improved survival to potential cureOncology20107823724820523084
   PubMed Web of Science ®Google Scholar
• GomezGGHutchisonRBKruseCAChemo-immunotherapy and chemo-adoptive immunotherapy of cancerCancer Treat Rev200127637540211908930
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• PolJKroemerGGalluzziLFirst oncolytic virus approved for melanoma immunotherapyOncoimmunology201551e111564126942095
   PubMed Web of Science ®Google Scholar
• RussellSJPengKWBellJCOncolytic virotherapyNat Biotechnol201230765867022781695
   PubMed Web of Science ®Google Scholar
• FuXTaoLZhangXAn oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancerCancer Gene Ther200714548048717290283
   PubMed Web of Science ®Google Scholar
• DuerstRJMorrisonLAHerpes simplex virus 2 virion host shutoff protein interferes with type I interferon production and responsivenessVirology2004322115816715063125
   PubMed Web of Science ®Google Scholar
• FuXTaoLCaiRPriggeJZhangXA mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virusMol Ther200613588289016569513
   PubMed Web of Science ®Google Scholar
• MacLeanARul-FareedMRobertsonLHarlandJBrownSMHerpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequenceJ Gen Virol199172Pt 36316391848598
   PubMed Web of Science ®Google Scholar
• LeibDAHarrisonTELasloKMMachalekMAMoormanNJVirginHWInterferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivoJ Exp Med199918946636729989981
   PubMed Web of Science ®Google Scholar
• KaufmanHLBinesSDOPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanomaFuture Oncol20106694194920528232
   PubMed Web of Science ®Google Scholar
• KohnoSILuoCNawaAOncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virusCancer Gene Ther2007141191892617693992
   PubMed Web of Science ®Google Scholar
• HwangTHMoonABurkeJA mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaMol Ther201119101913192221772252
   PubMed Web of Science ®Google Scholar
• HerseyPGallagherSIntralesional immunotherapy for melanomaJ Surg Oncol2014109432032624301265
   PubMed Web of Science ®Google Scholar
• StewartTJAbramsSIHow tumours escape mass destructionOncogene200827455894590318836470
   PubMed Web of Science ®Google Scholar
• BattagliaABuzzonettiABaranelloCMetastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancerCancer Immunol Immunother20095891363137319172271
   PubMed Web of Science ®Google Scholar
• WhitesideTLThe role of immune cells in the tumor microenvironmentCancer Treat Res200613010312416610705
   PubMedGoogle Scholar
• UgelSDelpozzoFDesantisGTherapeutic targeting of myeloid-derived suppressor cellsCurr Opin Pharmacol20099447048119616475
   PubMed Web of Science ®Google Scholar
• ZhaoQZhangWNingZA novel oncolytic herpes simplex virus type 2 has potent anti-tumor activityPLoS One201493e9310324671154
   PubMed Web of Science ®Google Scholar
• CiomeiMCrociVCiavolellaABallinariDPesentiEAntitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft modelClin Cancer Res20061292856286116675581
   PubMed Web of Science ®Google Scholar
• NakamuraKSasayamaATakahashiTYamajiTAn immune-modulating diet in combination with chemotherapy prevents cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing miceNutr Cancer201567691292026133950
   PubMed Web of Science ®Google Scholar
• SinhaPChornoguzOClementsVKArtemenkoKAZubarevRAOstrand-RosenbergSMyeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasLBlood2011117205381539021450901
   PubMed Web of Science ®Google Scholar
• Ottolino-PerryKAcunaSAAngaritaFAOncolytic vaccinia virus synergizes with irinotecan in colorectal cancerMol Oncol2015981539155226004084
   PubMed Web of Science ®Google Scholar
• FuXRiveraATaoLZhangXAn HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sitesOncotarget20156290291425460506
   PubMedGoogle Scholar
• BatemanARHarringtonKJKottkeTViral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cellsCancer Res200262226566657812438252
   PubMed Web of Science ®Google Scholar
• LiHDutuorAFuXZhangXInduction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor modelJ Gene Med20079316116917266169
   PubMed Web of Science ®Google Scholar
• HwangPMBunzFYuJFerredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cellsNat Med20017101111111711590433
   PubMed Web of Science ®Google Scholar
• SantiDVMcHenryCSRainesRTIvanetichKMKinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthaseBiochemistry19872626860686133126806
   PubMed Web of Science ®Google Scholar
• SauterBAlbertMLFranciscoLLarssonMSomersanSBhardwajNConsequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cellsJ Exp Med2000191342343410662788
   PubMed Web of Science ®Google Scholar
• AlpizarYAChainBCollinsMKTen years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapiesCancer Immunol Immunother20116081127113521479639
   PubMed Web of Science ®Google Scholar
• WengDSongBKoidoSCalderwoodSKGongJImmunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiationJ Immunol2013191275576323772032
   PubMed Web of Science ®Google Scholar
• KoidoSHommaSTakaharaACurrent immunotherapeutic approaches in pancreatic cancerClin Dev Immunol2011201126753921922022
   PubMed Web of Science ®Google Scholar
• BonertzAWeitzJPietschDHAntigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinomaJ Clin Invest2009119113311332119809157
   PubMed Web of Science ®Google Scholar
• SolitoSFalisiEDiaz-MonteroCMA human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cellsBlood201111882254226521734236
   PubMed Web of Science ®Google Scholar
• DempeSLavieMStruyfSAntitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitmentCancer Immunol Immunother201261112113212322576056
   PubMed Web of Science ®Google Scholar
• DranoffGJaffeeELazenbyAVaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunityProc Natl Acad Sci U S A1993908353935438097319
   PubMed Web of Science ®Google Scholar
• ZagozdzonRGolabJImmunomodulation by anticancer chemotherapy: more is not always better (review)Int J Oncol200118241742411172612
   PubMed Web of Science ®Google Scholar
• VincentJMignotGChalminF5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunityCancer Res20107083052306120388795
   PubMed Web of Science ®Google Scholar
• PernotSTermeMVoronTColorectal cancer and immunity: what we know and perspectivesWorld J Gastroenterol201420143738375024833840
   PubMed Web of Science ®Google Scholar
• KaufmanHLKimDWDeRaffeleGMitchamJCoffinRSKim-SchulzeSLocal and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanomaAnn Surg Oncol201017371873019915919
   PubMed Web of Science ®Google Scholar
• de VriesCRMonkenCELattimeECThe addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergyCancer Gene Ther201522315416225633483
   PubMed Web of Science ®Google Scholar
• SteinmanRMThe dendritic cell system and its role in immunogenicityAnnu Rev Immunol199192712961910679
   PubMed Web of Science ®Google Scholar
• ShiYLiuCHRobertsAIGranulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t knowCell Res200616212613316474424
   PubMed Web of Science ®Google Scholar
• DerubertisBGStilesBMBhargavaACytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanismsCancer Gene Ther200714659059717431402
   PubMed Web of Science ®Google Scholar
• GrossardtCEngelandCEBossowSGranulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccineHum Gene Ther201324764465423642239
   PubMed Web of Science ®Google Scholar
• AndtbackaRHRossMPuzanovIPatterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trialAnn Surg Oncol201623134169417727342831
   PubMed Web of Science ®Google Scholar
• KaufmanHLRubyCEHughesTSlingluffCLJrCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanomaJ Immunother Cancer201421124971166
   PubMedGoogle Scholar
• XieNWangYWangQLiFRGuoBLipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppressionBull Cancer2012995E55E6322522606
   PubMed Web of Science ®Google Scholar
• IsrayelyanAChouljenkoVNBaghianADavidATKearneyMTKousoulasKGHerpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in miceVirol J200856818518998
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanAROatesJCunninghamDWhy do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?Eur J Cancer19983445035099713300
   PubMed Web of Science ®Google Scholar
• ZhuangXZhangWChenYDoxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1BMC Cancer20121254923176143
   PubMed Web of Science ®Google Scholar